Circulating miRNAs as intercellular messengers, potential biomarkers and therapeutic targets for Type 2 diabetes

Epigenomics

Volumn 7, Issue 4, 2015, Pages 653-667

  Mirra, Paola ^a,b   Raciti, Gregory Alexander ^a,b   Nigro, Cecilia ^a,b   Fiory, Francesca ^a,b   D'Esposito, Vittoria ^a,b   Formisano, Pietro ^a,b   Beguinot, Francesco ^a,b   Miele, Claudia ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

Author keywords

biomarkers; cell to cell communication; circulating miRNAs; therapeutic targets; Type 2 diabetes

Indexed keywords

BIOLOGICAL MARKER; MICRORNA;

ADIPOCYTE; CELL COMMUNICATION; EXOSOME; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; BLOOD; DIABETES MELLITUS, TYPE 2; GENETICS; SECOND MESSENGER;

ANIMALS; BIOMARKERS; CELL COMMUNICATION; DIABETES MELLITUS, TYPE 2; HUMANS; MICRORNAS; SECOND MESSENGER SYSTEMS;

EID: 84933526715     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.15.18     Document Type: Review

References (98)

1. Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature 447(7143), 433-440 (2007).
2. Keating ST, El-Osta A. Epigenetic changes in diabetes. Clin. Genet. 84(1), 1-10 (2013).
3. Tetreault N, De Guire V. miRNAs: their discovery, biogenesis and mechanism of action. Clin. Biochem. 46(10-11), 842-845 (2013).
4. Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu. Rev. Biochem. 79, 351-379 (2010).
5. Sato F, Tsuchiya S, Meltzer SJ, Shimizu K. MicroRNAs and epigenetics. FEBS J. 278(10), 1598-1609 (2011).
6. Liu C, Teng ZQ, Mcquate AL et al. An epigenetic feedback regulatory loop involving microRNA-195 and MBD1 governs neural stem cell differentiation. PLoS ONE 8(1), e51436 (2013).
7. Guay C, Roggli E, Nesca V, Jacovetti C, Regazzi R. Diabetes mellitus, a microRNA-related disease? Transl. Res. 157(4), 253-264 (2011).
8. Rottiers V, Naar AM. MicroRNAs in metabolism and metabolic disorders. Nat. Rev. Mol. Cell. Biol. 13(4), 239-250 (2012).
9. Frost RJ, Olson EN. Control of glucose homeostasis and insulin sensitivity by the Let-7 family of microRNAs. Proc. Natl Acad. Sci. USA 108(52), 21075-21080 (2011).
10. Zhu H, Shyh-Chang N, Segre AV et al. The Lin28/let-7 axis regulates glucose metabolism. Cell 147(1), 81-94 (2011).
11. Ling HY, Hu B, Hu XB et al. MiRNA-21 reverses high glucose and high insulin induced insulin resistance in 3T3-L1 adipocytes through targeting phosphatase and tensin homologue. Exp. Clin. Endocrinol. Diabetes. 120(9), 553-559 (2012).
12. He A, Zhu L, Gupta N, Chang Y, Fang F. Overexpression of micro ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin resistance in 3T3-L1 adipocytes. Mol. Endocrinol. 21(11), 2785-2794 (2007).
13. Herrera BM, Lockstone HE, Taylor JM et al. Global microRNA expression profiles in insulin target tissues in a spontaneous rat model of Type 2 diabetes. Diabetologia 53(6), 1099-1109 (2010).
14. Pandey AK, Verma G, Vig S, Srivastava S, Srivastava AK, Datta M. miR-29a levels are elevated in the db/db mice liver and its overexpression leads to attenuation of insulin action on PEPCK gene expression in HepG2 cells. Mol. Cell. Endocrinol. 332(1-2), 125-133 (2011).
15. Davalos A, Goedeke L, Smibert P et al. miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc. Natl Acad. Sci. USA 108(22), 9232-9237 (2011).
16. Rayner KJ, Esau CC, Hussain FN et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 478(7369), 404-407 (2011).
17. Rayner KJ, Sheedy FJ, Esau CC et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J. Clin. Invest. 121(7), 2921-2931 (2011).
18. Lee J, Kemper JK. Controlling SIRT1 expression by microRNAs in health and metabolic disease. Aging 2(8), 527-534 (2010).
19. Chen YH, Heneidi S, Lee JM et al. miRNA-93 inhibits GLUT4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin resistance. Diabetes 62(7), 2278-2286 (2013).
20. Trajkovski M, Hausser J, Soutschek J et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 474(7353), 649-653 (2011).
21. Ryu HS, Park SY, Ma D, Zhang J, Lee W. The induction of microRNA targeting IRS-1 is involved in the development of insulin resistance under conditions of mitochondrial dysfunction in hepatocytes. PLoS ONE 6(3), e17343 (2011).
22. Jordan SD, Kruger M, Willmes DM et al. Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. Nat. Cell. Biol. 13(4), 434-446 (2011).
23. Takanabe R, Ono K, Abe Y et al. Up-regulated expression of microRNA-143 in association with obesity in adipose tissue of mice fed high-fat diet. Biochem. Biophys. Res. Commun. 376(4), 728-732 (2008).
24. Lu H, Buchan RJ, Cook SA. MicroRNA-223 regulates Glut4 expression and cardiomyocyte glucose metabolism. Cardiovasc. Res. 86(3), 410-420 (2010).
25. Ling HY, Ou HS, Feng SD et al. Changes in microRNA (miR) profile and effects of miR-320 in insulin-resistant 3T3-L1 adipocytes. Clin. Exp. Pharmacol. Physiol. 36(9), e32-e39 (2009).
26. Lee H, Jee Y, Hong K, Hwang GS, Chun KH. MicroRNA-494, upregulated by tumor necrosis factor-alpha, desensitizes insulin effect in C2C12 muscle cells. PLoS ONE 8(12), e83471 (2013).
27. Kornfeld JW, Baitzel C, Konner AC et al. Obesity-induced overexpression of miR-802 impairs glucose metabolism through silencing of Hnf1b. Nature 494(7435), 111-115 (2013).
28. Ramachandran D, Roy U, Garg S, Ghosh S, Pathak S, Kolthur-Seetharam U. Sirt1 and mir-9 expression is regulated during glucose-stimulated insulin secretion in pancreatic beta-islets. FEBS J. 278(7), 1167-1174 (2011).
29. Plaisance V, Abderrahmani A, Perret-Menoud V, Jacquemin P, Lemaigre F, Regazzi R. MicroRNA-9 controls the expression of Granuphilin/Slp4 and the secretory response of insulin-producing cells. J. Biol. Chem. 281(37), 26932-26942 (2006).
30. Pullen TJ, Da Silva Xavier G, Kelsey G, Rutter GA. miR-29a and miR-29b contribute to pancreatic beta-cell-specific silencing of monocarboxylate transporter 1 (Mct1). Mol. Cell. Biol. 31(15), 3182-3194 (2011).
31. Roggli E, Gattesco S, Caille D et al. Changes in microRNA expression contribute to pancreatic beta-cell dysfunction in prediabetic NOD mice. Diabetes 61(7), 1742-1751 (2012).
32. Tang X, Muniappan L, Tang G, Ozcan S. Identification of glucose-regulated miRNAs from pancreatic {beta} cells reveals a role for miR-30d in insulin transcription. RNA 15(2), 287-293 (2009).
33. Zhao X, Mohan R, Ozcan S, Tang X. MicroRNA-30d induces insulin transcription factor MafA and insulin production by targeting mitogen-activated protein 4 kinase 4 (MAP4K4) in pancreatic beta-cells. J. Biol. Chem. 287(37), 31155-31164 (2012).
34. Lovis P, Roggli E, Laybutt DR et al. Alterations in microRNA expression contribute to fatty acid-induced pancreatic beta-cell dysfunction. Diabetes 57(10), 2728-2736 (2008).
35. Roggli E, Britan A, Gattesco S et al. Involvement of microRNAs in the cytotoxic effects exerted by proinflammatory cytokines on pancreatic beta-cells. Diabetes 59(4), 978-986 (2010).
36. Yamakuchi M, Lowenstein CJ. MiR-34, SIRT1 and p53: the feedback loop. Cell Cycle 8(5), 712-715 (2009).
37. Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl Acad. Sci. USA 105(36), 13421-13426 (2008).
38. Esguerra JL, Bolmeson C, Cilio CM, Eliasson L. Differential glucose-regulation of microRNAs in pancreatic islets of nonobese Type 2 diabetes model Goto-Kakizaki rat. PLoS ONE 6(4), e18613 (2011).
39. Zhao H, Guan J, Lee HM et al. Up-regulated pancreatic tissue microRNA-375 associates with human Type 2 diabetes through beta-cell deficit and islet amyloid deposition. Pancreas 39(6), 843-846 (2010).
40. Kloosterman WP, Lagendijk AK, Ketting RF, Moulton JD, Plasterk RH. Targeted inhibition of miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet development. PLoS Biol. 5(8), e203 (2007).
41. Poy MN, Eliasson L, Krutzfeldt J et al. A pancreatic isletspecific microRNA regulates insulin secretion. Nature 432(7014), 226-230 (2004).
42. Poy MN, Hausser J, Trajkovski M et al. miR-375 maintains normal pancreatic alpha-and beta-cell mass. Proc. Natl Acad. Sci. USA 106(14), 5813-5818 (2009).
43. El Ouaamari A, Baroukh N, Martens GA, Lebrun P, Pipeleers D, Van Obberghen E. miR-375 targets 3'-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic beta-cells. Diabetes 57(10), 2708-2717 (2008).
44. Villeneuve LM, Kato M, Reddy MA, Wang M, Lanting L, Natarajan R. Enhanced levels of microRNA-125b in vascular smooth muscle cells of diabetic db/db mice lead to increased inflammatory gene expression by targeting the histone methyltransferase Suv39h1. Diabetes 59(11), 2904-2915 (2010).
45. Feng B, Cao Y, Chen S, Ruiz M, Chakrabarti S. miRNA-1 regulates endothelin-1 in diabetes. Life Sci. 98(1), 18-23 (2014).
46. Zeng J, Xiong Y, Li G et al. MiR-21 is overexpressed in response to high glucose and protects endothelial cells from apoptosis. Exp. Clin. Endocrinol. Diabetes 121(7), 425-430 (2013).
47. Zampetaki A, Kiechl S, Drozdov I et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in Type 2 diabetes. Circ. Res. 107(6), 810-817 (2010).
48. Togliatto G, Trombetta A, Dentelli P et al. Unacylated ghrelin (UnAG) induces oxidative stress resistance in a glucose intolerance mouse model and peripheral artery disease by restoring endothelial cell miR-126 expression. Diabetes doi:10.2337/db14-0991 (2014).
49. Feng B, Chen S, Mcarthur K et al. miR-146a-Mediated extracellular matrix protein production in chronic diabetes complications. Diabetes 60(11), 2975-2984 (2011).
50. Li Y, Song YH, Li F, Yang T, Lu YW, Geng YJ. MicroRNA-221 regulates high glucose-induced endothelial dysfunction. Biochem. Biophys. Res. Commun. 381(1), 81-83 (2009).
51. Togliatto G, Trombetta A, Dentelli P, Rosso A, Brizzi MF. MIR221/MIR222-driven post-transcriptional regulation of P27KIP1 and P57KIP2 is crucial for high-glucose-and AGE-mediated vascular cell damage. Diabetologia 54(7), 1930-1940 (2011).
52. Caporali A, Meloni M, Vollenkle C et al. Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation 123(3), 282-291 (2011).
53. Lotvall J, Valadi H. Cell to cell signalling via exosomes through esRNA. Cell. Adh. Migr. 1(3), 156-158 (2007).
54. Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18(10), 997-1006 (2008).
55. Hunter MP, Ismail N, Zhang X et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE 3(11), e3694 (2008).
56. Lawrie CH, Gal S, Dunlop HM et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 141(5), 672-675 (2008).
57. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105(30), 10513-10518 (2008).
58. Skog J, Wurdinger T, Van Rijn S et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell. Biol. 10(12), 1470-1476 (2008).
59. Vencio EF, Pascal LE, Page LS et al. Embryonal carcinoma cell induction of miRNA and mRNA changes in co-cultured prostate stromal fibromuscular cells. J. Cell. Physiol. 226(6), 1479-1488 (2011).
60. Weber JA, Baxter DH, Zhang S et al. The microRNA spectrum in 12 body fluids. Clin. Chem. 56(11), 1733-1741 (2010).
61. Arroyo JD, Chevillet JR, Kroh EM et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl Acad. Sci. USA 108(12), 5003-5008 (2011).
62. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic. Acids. Res. 39(16), 7223-7233 (2011).
63. Camussi G, Deregibus MC, Bruno S, Grange C, Fonsato V, Tetta C. Exosome/microvesicle-mediated epigenetic reprogramming of cells. Am. J. Cancer Res. 1(1), 98-110 (2011).
64. Gyorgy B, Szabo TG, Pasztoi M et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell. Mol. Life Sci. 68(16), 2667-2688 (2011).
65. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell. Biol. 13(4), 423-433 (2011).
66. Wagner J, Riwanto M, Besler C et al. Characterization of levels and cellular transfer of circulating lipoproteinbound microRNAs. Arterioscler. Thromb. Vasc. Biol. 33(6), 1392-1400 (2013).
67. Hulsmans M, Holvoet P. MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease. Cardiovasc. Res. 100(1), 7-18 (2013).
68. Hulsmans M, Holvoet P. MicroRNAs as early biomarkers in obesity and related metabolic and cardiovascular diseases. Curr. Pharm. Des. 19(32), 5704-5717 (2013).
69. Park NJ, Zhou H, Elashoff D et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin. Cancer Res. 15(17), 5473-5477 (2009).
70. Hanke M, Hoefig K, Merz H et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol. Oncol. 28(6), 655-661 (2010).
71. Montecalvo A, Larregina At, Shufesky WJ et al. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood 119(3), 756-766 (2012).
72. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J. Biol. Chem. 285(23), 17442-17452 (2010).
73. Mittelbrunn M, Gutierrez-Vazquez C, Villarroya-Beltri C et al. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat. Commun. 2, 282 (2011).
74. Iguchi H, Kosaka N, Ochiya T. Versatile applications of microRNA in anti-cancer drug discovery: from therapeutics to biomarkers. Curr. Drug Discov. Technol. 7(2), 95-105 (2010).
75. Kogure T, Lin WL, Yan IK, Braconi C, Patel T. Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology 54(4), 1237-1248 (2011).
76. Liu AY, Pascal LE, Vencio RZ, Vencio EF. Stromal-epithelial interactions in early neoplasia. Cancer Biomark 9(1-6), 141-155 (2010).
77. Yang M, Chen J, Su F et al. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol. Cancer 10, 117 (2011).
78. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell. Biol. 9(6), 654-659 (2007).
79. Ismail N, Wang Y, Dakhlallah D et al. Macrophage microvesicles induce macrophage differentiation and miR-223 transfer. Blood 121(6), 984-995 (2013).
80. Zhang Y, Liu D, Chen X et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol. Cell. 39(1), 133-144 (2010).
81. Liu Y, Zhao L, Li D et al. Microvesicle-delivery miR-150 promotes tumorigenesis by up-regulating VEGF, and the neutralization of miR-150 attenuate tumor development. Protein Cell. 4(12), 932-941 (2013).
82. Zernecke A, Bidzhekov K, Noels H et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci. Signal. 2(100), ra81 (2009).
83. Jansen F, Yang X, Hoelscher M et al. Endothelial microparticle-mediated transfer of MicroRNA-126 promotes vascular endothelial cell repair via SPRED1 and is abrogated in glucose-damaged endothelial microparticles. Circulation 128(18), 2026-2038 (2013).
84. Mocharla P, Briand S, Giannotti G et al. AngiomiR-126 expression and secretion from circulating CD34(+) and CD14(+) PBMCs: role for proangiogenic effects and alterations in type 2 diabetics. Blood 121(1), 226-236 (2013).
85. Hergenreider E, Heydt S, Treguer K et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat. Cell. Biol. 14(3), 249-256 (2012).
86. Ogawa R, Tanaka C, Sato M et al. Adipocyte-derived microvesicles contain RNA that is transported into macrophages and might be secreted into blood circulation. Biochem. Biophys. Res. Commun. 398(4), 723-729 (2010).
87. Muller G. Take-over: multiple mechanisms of interadipocyte communication. J. Mol. Cell. Biol. 3(2), 81-90 (2011).
88. Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat. Rev. Clin. Oncol. 11(3), 145-156 (2014).
89. Kong L, Zhu J, Han W et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed Type 2 diabetes: a clinical study. Acta Diabetol. 48(1), 61-69 (2011).
90. Karolina DS, Tavintharan S, Armugam A et al. Circulating miRNA profiles in patients with metabolic syndrome. J. Clin. Endocrinol. Metab. 97(12), E2271-2276 (2012).
91. Bouchie A. First microRNA mimic enters clinic. Nat. Biotechnol. 31(7), 577 (2013).
92. Janssen HL, Reesink HW, Lawitz EJ et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368(18), 1685-1694 (2013).
93. Janssen HL, Kauppinen S, Hodges MR. HCV infection and miravirsen. N. Engl. J. Med. 369(9), 878 (2013).
94. Gebert LF, Rebhan MA, Crivelli SE, Denzler R, Stoffel M, Hall J. Miravirsen (SPC3649) can inhibit the biogenesis of miR-122. Nucleic Acids Res. 42(1), 609-621 (2014).
95. Elmen J, Lindow M, Silahtaroglu A et al. Antagonism of microRNA-122 in mice by systemically administered LNAantimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 36(4), 1153-1162 (2008).
96. Montgomery RL, Hullinger TG, Semus HM et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 124(14), 1537-1547 (2011).
97. Grueter CE, Van Rooij E, Johnson BA et al. A cardiac microRNA governs systemic energy homeostasis by regulation of MED13. Cell 149(3), 671-683 (2012).
98. Ohno S, Takanashi M, Sudo K et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol. Ther. 21(1), 185-191 (2013).